SK Bioscience Applies for Phase 3 Clinical Trial Plan of COVID-19 Vaccine in Nepal
[Asia Economy Reporter Minji Lee] SK Bioscience announced on the 8th that it has applied for a Phase 3 clinical trial plan for the heterologous booster shot of the COVID-19 vaccine GBP510 in Nepal.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- Signed Without Viewing for 1.6 Billion Won... Jamsil and Seongbuk Jeonse Prices Jump 200 Million Won in a Month [Real Estate AtoZ]
- "Groups of 5 or More Now Restricted"... Unrelenting Running Craze Leaves Citizens and Police Exhausted
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
The company stated, “GBP510 is a SARS-CoV-2 recombinant protein nanoparticle vaccine using the adjuvant AS03. It is expected to enhance the immune response, which decreases over time after the primary vaccination, through a heterologous booster shot, while also ensuring sufficient safety.”
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
